艾地苯醌协同抗抑郁药治疗对急性脑梗死后抑郁患者情绪障碍及脑功能恢复的影响分析
Effect of Butylphthalide Soft Capsule Combined with Antidepressants on Emotional Disorder and Brain Function Recovery in Patients with Depression after Acute Cerebral Infarction
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2020, 47(5) |
| 作者 |
|
| 作者单位 |
江西省上饶市人民医院 ;
|
| 摘要 |
目的：探究急性脑梗死（ACI）后抑郁症患者应用艾地苯醌结合抗抑郁药物治疗对患者情绪障碍以及其脑功能的恢复效果影响。方法：纳入本院2015年1月至2019年6月收治62例ACI并抑郁症患者，随机将患者分为常规组（n=31）与研究组（n=31）。常规组患者均予以常规ACI治疗同时结合草酸艾司西酞普兰片进行治疗，研究组患者均予以常规ACI治疗同时结合草酸艾司西酞普兰片+艾地苯醌进行治疗。对比两组患者疗效、美国国立卫生院脑卒中评分量表（NIHSS）、卒中评分量表（CSS）评分、Zung抑郁自评评分表（SDS）、汉密尔顿抑郁评分表（HAMD）以及药物不良反应情况。结果：治疗2个月后研究组患者治疗总有效率相比常规组明显更高（P<0.05）；治疗2个月两组患者NIHSS评分与CSS评分相比治疗前均有明显降低（P<0.05）；治疗2个月研究组患者NIHSS评分与CSS评分相比常规组明显更低（P<0.05）；治疗2个月两组患者HAMD-17评分与SDS评分相比治疗前均有明显降低（P<0.05）；治疗2个月研究组患者HAMD-17评分与SDS评分对比常规组明显更低（P<0.05）；两组患者治疗后不良反应发生率对比未见显著差异（P>0.05）。结论：临床针对ACI并抑郁症患者予以艾地苯醌与抗抑郁药物联用治疗可有效改善患者神经功能，改善患者的抑郁状态，该治疗方法安全可靠，可促进ACI并抑郁症患者治疗后的康复。
|
| Abstract |
OBJECTIVE: To investigate the effects of idebenone combined with antidepressant medication on patients with acute cerebral infarction (ACI) after depression and their brain function recovery. METHODS: Sixty-two patients with ACI and depression were enrolled from January 2015 to June 2019. Patients were randomized into a regular group (n=31) and a study group (n=31). Patients in the conventional group were treated with conventional ACI and escitalopram oxalate tablets. Patients in the study group were treated with conventional ACI and combined with escitalopram oxalate + idebenone. Compare the efficacy of the two groups, the National Institute of Health Stroke Scale (NIHSS), the Stroke Scale (CSS) score, the Zung Depression Self-Assessment Scale (SDS), the Hamilton Depression Score (HAMD), and adverse drug reactions. RESULTS: After 2 months of treatment, the total effective rate of the study group was significantly higher than that of the conventional group (P < 0.05); the NIHSS score of the two groups was significantly lower than that of the CSS score before treatment (P < 0.05); the NIHSS score of the study group was significantly lower than that of the conventional group after 2 months of treatment (P < 0.05); The HAMD-17 score of the two groups was significantly lower than that of the SDS score before treatment (P < 0.05); the HAMD-17 score of the two-month study group was significantly lower than that of the conventional group (P < 0.05); there was no significant difference in the incidence of adverse reactions between the two groups after treatment (P > 0.05). CONCLUSION: Clinically, the combination of idebenone and antidepressant in patients with ACI and depression can effectively improve the neurological function of patients and improve the depression status of patients. The treatment is safe and reliable, and can promote the rehabilitation of patients with ACI and depression.
|
| 关键词 |
艾地苯醌；抗抑郁药物；急性脑梗死后抑郁；脑功能恢复；情绪障碍
|
| KeyWord |
Idebenone; Antidepressants; Depression after Acute Cerebral Infarction; Brain Function Recovery; Emotional Disorder
|
| 基金项目 |
|
| 页码 |
982-984 |
张爱莲*.
艾地苯醌协同抗抑郁药治疗对急性脑梗死后抑郁患者情绪障碍及脑功能恢复的影响分析 [J].
国际精神病学杂志.
2020; 47; (5).
982 - 984.